Introduction
============

Schwannoma or neurilemmoma is a benign tumor of neuroectodermal origin that is derived from Schwann cells of the neural sheath. [@JR1041sr-1] [@JR1041sr-2] [@JR1041sr-3] In 1910, Verocay first described the microscopic features of this tumor under the term neurinoma. [@JR1041sr-4] The term schwannoma was introduced by Masson in 1932. [@JR1041sr-5] Later, in 1935, Stout [@JR1041sr-3] used the term, neurilemmoma, and further detailed its histopathology. In 1940, Tarlov described the tumor to be of fibroblastic origin and coined the term perineural fibroblastoma. [@JR1041sr-6] About between 25 and 45% of all schwannomas are found in the head and neck region, and only between 1 and 12% of them have an intraoral origin. [@JR1041sr-7] [@JR1041sr-8] [@JR1041sr-9] However, the palatal location is rare. The present article presents a specific systematic review of the published literature on palatal schwannomas, along with an illustrative case.

Review of the Literature
========================

Case Presentation
-----------------

A 16-year-old female presented with a complaint of a painless swelling over the palatal region. She first noticed a small nodule 2 months before, which was gradually increasing in size. She was otherwise healthy and did not report a history of alcohol consumption or of smoking. No genetic or syndromic abnormalities were reported from her family. Her laboratory reports were unremarkable. In the intraoral examination, a solitary, nontender, firm swelling, ∼ 2.5 × 2 cm in dimension, was noted over the left soft palate. The tumor had a whitish-yellow appearance, and the overlying mucosa was ulcerated ( [Fig. 1](#FI1041sr-1){ref-type="fig"} ). A computed tomography (CT) scan revealed a well-defined, hypodense, soft tissue lesion measuring 27.8 × 21.6 × 18.2 mm involving the left side of the soft palate ( [Fig. 2](#FI1041sr-2){ref-type="fig"} ). With a probable clinical diagnosis of benign salivary gland tumor, the lesion was completely excised and the defect was allowed to heal by secondary intention. The histological examination of the lesion revealed a predominant presence of Antoni A areas with spindle-shaped cells arranged in a palisading pattern and central acellular areas representing Verocay bodies ( [Figs. 3](#FI1041sr-3){ref-type="fig"} and [4](#FI1041sr-4){ref-type="fig"} ). Some areas also showed a hypocellular and less organized arrangement, as seen in the Antoni B type. The immunohistochemical (IHC) examination with S-100 protein revealed intense positivity in the cells of the tumor ( [Fig. 5](#FI1041sr-5){ref-type="fig"} ). The tumor cells also showed positive expression of SRY-related HMG-box 10 (SOX-10) protein ( [Fig. 6](#FI1041sr-6){ref-type="fig"} ). Based on the clinical behavior, as well as on the histological and IHC findings, the final diagnosis was of a benign schwannoma of the soft palate (conventional variant).

![Painless swelling over the left soft palate with ulceration of the overlying mucosa.](10-1055-s-0039-1692635-i1041sr-1){#FI1041sr-1}

![Computed tomography shows a hypodense, soft tissue lesion involving the soft palate on left side (red arrow).](10-1055-s-0039-1692635-i1041sr-2){#FI1041sr-2}

![Section showing a spindle cell tumor and areas of collagenization (Hematoxylin and eosin staining; 100x).](10-1055-s-0039-1692635-i1041sr-3){#FI1041sr-3}

![Section showing proliferating fusiform cells arranged in palisading pattern and areas of acellular eosinophilic regions representing Verocay bodies (Hematoxylin and eosin staining; 200x).](10-1055-s-0039-1692635-i1041sr-4){#FI1041sr-4}

![Section showing tumor cells expressing strong nuclear and cytoplasmic S-100.](10-1055-s-0039-1692635-i1041sr-5){#FI1041sr-5}

![Section showing tumor cells expressing SRY-related HMG-box 10 (SOX-10).](10-1055-s-0039-1692635-i1041sr-6){#FI1041sr-6}

Methodology
-----------

A systematic review of the literature was performed in August 2018 on 2 different databases (PubMed and Google Scholar). The database was searched for full-length articles and abstracts using the following Medical Subject Headings (MeSH): *palate* , AND *schwannoma* , AND/OR *neurilemoma* , AND/OR *neurilemmoma* AND *hard* AND/OR *soft palate* , AND/OR *intraoral* MINUS *tongue* , *vestibule* and other intraoral anatomical locations. The search included synonymous terms and was confined to studies or reports in humans. The review included isolated case reports or articles with up to 2 cases of palatal schwannomas published after 1984 in English, German or Japanese. Articles containing \> 2 cases of palatal schwannoma, or larger case series, were not included. Cases diagnosed as malignant schwannoma at the initial presentation were not included. No age limits were applied. Information from the included articles was collected in a predesigned Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheet.

Result
======

A total of 46 cases (45 published cases and an illustrative case) of palatal schwannoma were included in the present review. From the included articles, clinical, histopathological, radiological, and treatment findings were charted ( [Tables 1](#TB1041sr-1){ref-type="table"} and [2](#TB1041sr-2){ref-type="table"} ). [@JR1041sr-10] [@JR1041sr-11] [@JR1041sr-12] [@JR1041sr-13] [@JR1041sr-14] [@JR1041sr-15] [@JR1041sr-16] [@JR1041sr-17] [@JR1041sr-18] [@JR1041sr-19] [@JR1041sr-20] [@JR1041sr-21] [@JR1041sr-22] [@JR1041sr-23] [@JR1041sr-24] [@OR1041sr-25] [@JR1041sr-26] [@JR1041sr-27] [@JR1041sr-28] [@JR1041sr-29] [@JR1041sr-30] [@JR1041sr-31] [@JR1041sr-32] [@JR1041sr-33] [@JR1041sr-34] [@JR1041sr-35] [@JR1041sr-36] [@JR1041sr-37] [@JR1041sr-38] [@JR1041sr-39] [@JR1041sr-40] [@JR1041sr-41] [@JR1041sr-42] [@JR1041sr-43] [@JR1041sr-44] [@JR1041sr-45] [@JR1041sr-46] [@JR1041sr-47] [@JR1041sr-48] [@JR1041sr-49] [@JR1041sr-50] [@JR1041sr-51] [@JR1041sr-52] [@JR1041sr-53] [@JR1041sr-54]

###### Review of previously reported palatal schwannomas

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case authors                                  Year   Age/gender   Country   Lesion duration (months)   Clinical symptoms                                                     Lesion size (cm)   Site   Surgical procedure                                             IHC                                                                            F/U         Recurrence   MT   Variant
  --------------------------------------------- ------ ------------ --------- -------------------------- --------------------------------------------------------------------- ------------------ ------ -------------------------------------------------------------- ------------------------------------------------------------------------------ ----------- ------------ ---- --------------
  Yamashita et al [@JR1041sr-10]                1985   19/F         Japan     NI                         swelling                                                              1.5 × 1.2          RSP    CEN                                                            S-100  + ve                                                                    NI          no           no   cv

  Jones et al [@JR1041sr-11]                    1987   29/F         UK        24                         painless swelling                                                     2.5                RSP    CEN                                                            NI                                                                             3 years     no           no   cv

  Hieda et al [@JR1041sr-12]                    1987   44/M         Japan     4                          tumor                                                                 1.5 × 1.2          RHP    WLE & tumor resected en bloc                                   S-100  + ve                                                                    4 months    no           no   cv

  Krolls et al [@JR1041sr-13]                   1994   21/F         USA       12                         tumor, discomfort during eating and talking                           NI                 LHP    Excision Bx                                                    NI                                                                             3 years     yes          no   plx

  Amir et al [@JR1041sr-14]                     2002   40/M         USA       3                          FB sensation, dysphagia, garbled speech                               5 × 4              EHP    WLE; secondary intention closure                               S-100  + ve                                                                    NI          no           no   cv

  Rabbels et al [@JR1041sr-15]                  2005   11/F         Germany   3                          painless swelling                                                     2 × 2              RHP    WLE; collagen closure                                          S-100, Vimentin & NSE  + ve                                                    2 years     no           no   cv

  López-Carriches et al [@JR1041sr-16]          2009   15/M         Spain     3                          swelling                                                              1 × 1.5            LHP    Incision Bx-CEN                                                S-100  + ve                                                                    2 years     no           no   cv

  Baliga et al [@JR1041sr-17]                   2009   40/F         India     recently                   painless swelling                                                     NI                 LSP    FNAC (IC)-WLE; collagen closure                                NI                                                                             10 years    no           no   cv

  Murthy et al [@JR1041sr-18]                   2009   28/F         India     4                          swelling, bleeding, with tongue pressure                              1.5 × 1.5          LHP    Incision Bx- CEN                                               NI                                                                             NI          no           no   cv

  Lollar et al [@JR1041sr-19]                   2010   33/M         USA       3                          enlarging mass                                                        2 × 2              MHP    Shave Bx- WLE                                                  S-100 & Vimentin  + ve                                                         NI          no           no   cv

  Parikh et al [@JR1041sr-20]                   2010   64/F         India     36                         enlarging mass                                                        2 × 2              MHP    CEN                                                            NI                                                                             NI          no           no   cv

  Isildak et al [@JR1041sr-21]                  2010   45/F         Turkey    180                        enlarging mass                                                        2 × 2              RHP    WLE                                                            S-100 + ve; Actin - ve                                                         NI          no           no   cv with NFLA

  Santos et al [@JR1041sr-22]                   2010   41/F         Brazil    60                         painless nodule                                                       3 × 1              RHP    CEN                                                            NI                                                                             NI          no           no   cv

  Santos et al [@JR1041sr-22]                   2010   53/F         Brazil    6                          painless swelling                                                     3 × 3              HP     CEN                                                            S-100  + ve                                                                    NI          no           no   cv

  Chawla et al [@JR1041sr-23]                   2011   9/M          UK        0.75\                      painless swelling, difficulty in eating and swallowing                1 × 1              RSP    CEN                                                            NI                                                                             1 year      no           no   cv
                                                                              (3 weeks)                                                                                                                                                                                                                                                                                              

  dos Santos et al [@JR1041sr-24]               2011   3/F          Brazil    6                          enlarging painless mass                                               1.6                RHP    CEN                                                            S-100, Vimentin, EMA, GFAP, CD-57 & CD-56 + ve, NF; AE1/AE3, & Calponin - ve   1 year      no           no   plx

  Dhupar et al [@OR1041sr-25]                   2012   10/M         India     5                          swelling, dysphagia, garbled speech, bleeding                         3 × 2              MHP    WLE; palatal splinting                                         NI                                                                             NI          no           no   cv

  Handschel et al [@JR1041sr-26]                2012   32/M         Germany   24                         enlarging nodule                                                      1 × 2              RHP    Incision Bx-WLE; prosthesis placement                          S-100 +ve                                                                      6 months    no           no   cv

  Shetty et al [@JR1041sr-27]                   2012   70/F         India     24                         enlarging painless mass, discomfort on mastication                    2 × 2              RHP    FNAC (IC)-CEN                                                  NI                                                                             8 months    no           no   cv

  Prasanna Kumar et al [@JR1041sr-28]           2012   18/m         India     22                         enlarging painless mass                                               3 × 2.5            LHP    CEN                                                            NI                                                                             NI          no           no   cv

  [Kapetanakis]{.ul} et al [@JR1041sr-29]       2012   21/F         Greece    14                         enlarging painless mass                                               1.5 × 2            SP     WLE                                                            S-100 + ve                                                                     NI          no           no   plx

  Rahpeyma et al [@JR1041sr-30]                 2012   12/F         Iran      3                          enlarging painless mass                                               3                  RSP    Incision Bx-CEN; buccinators myomucosal flap closure           S-100 + ve                                                                     6 months    no           no   cv

  Venkatachala et al [@JR1041sr-31]             2013   43/M         India     1                          swelling and dysphagia                                                2 × 2              RSP    CEN                                                            S-100 + ve                                                                     NI          no           no   cv

  [Gainza-Cirauqui]{.ul} et al [@JR1041sr-32]   2013   35/F         Spain     60                         enlarging tumor                                                       2 × 1.5            MHP    FNAC(IC)-CEN                                                   S-100 + ve                                                                     2 years     no           no   ancient

  Chikhale et al [@JR1041sr-33]                 2013   42/F         India     ID                         ID                                                                    2 × 2              LHP    CEN                                                            NI                                                                             NI          no           no   cv

  Moradzadeh Khiavi et al [@JR1041sr-34]        2014   21/M         Iran      2                          painless mass                                                         2 × 2              MHP    Incision Bx-CEN                                                S-100 + ve                                                                     6 months    no           no   cv

  Aboh et al [@JR1041sr-35]                     2014   49/F         Italy     240                        enlarging mass, difficulty with oral hygiene, phonation and dyspnea   4 × 3              LHP    CEN                                                            NI                                                                             1 year      no           no   cv

  Parhar et al [@JR1041sr-36]                   2014   34/F         India     12                         enlarging painless mass                                               2 × 1.5            RHP    Incision Bx - CEN                                              NI                                                                             NI          no           no   cv

  Sahoo et al [@JR1041sr-37]                    2014   28/M         India     48                         enlarging mass, pain since 3 months                                   3                  LHP    FNAC -WLE                                                      S-100 + ve, SMA - ve                                                           10 months   no           no   cv

  Kudoh et al [@JR1041sr-38]                    2015   84/M         Japan     ID                         ID                                                                    3                  LHP    Incision Bx-partial maxillectomy; split-thickness skin graft   S-100 + ve, K ~i~ -67 + ve rate 1%                                             29 months   no           no   cv

  Meundi et al [@JR1041sr-39]                   2015   20/F         India     ID                         ID                                                                    1 × 3              LHP    FNAC(IC)-CEN                                                   NI                                                                             2 months    no           no   cv

  Tibbetts et al [@JR1041sr-40]                 2015   11/F         USA       12                         enlarging mass                                                        1                  RSP    WLE                                                            NI                                                                             1 month     no           no   cv

  Yaga et al [@JR1041sr-41]                     2015   28/M         India     12                         enlarging nodule, dysphagia                                           4 × 4              RSP    FNAC-CEN                                                       NI                                                                             NI          no           no   cv

  Karatas et al [@JR1041sr-42]                  2015   36/F         Turkey    36                         enlarging mass                                                        3 × 5              RHP    CEN                                                            S-100 & Vimentin + ve                                                          18 months   no           no   cv

  Morgan et al [@JR1041sr-43]                   2015   16/F         India     12                         painless swelling                                                     2 × 3              RHP    FNAC (IC)- CEN                                                 NI                                                                             NI          no           no   cv

  Sicca et al [@JR1041sr-44]                    2015   13/F         Italy     couple of weeks            rapidly growing mass                                                  1.5                LSP    Incision Bx- CEN                                               S-100 + ve                                                                     6 months    no           no   cv

  Barhmi et al [@JR1041sr-45]                   2016   13/NI        Morocco   6                          painless swelling                                                     2                  RSP    Incision Bx-CEN                                                S-100 + ve                                                                     2 years     no           no   cv

  Shi et al [@JR1041sr-46]                      2016   56/F         USA       ID                         ID                                                                    1.6 × 2            LSP    Incision Bx-CEN                                                S-100 + ve; AE1/AE3 cytokeratin -ve                                            11 days     no           no   cv

  Eroglu et al [@JR1041sr-47]                   2017   29/M         Turkey    ID                         ID                                                                    2 × 2              LHP    Enucleated (y-shaped incision); primary closure                NI                                                                             18 months   no           no   cv

  Poonja et al [@JR1041sr-48]                   2017   30/F         India     8                          swelling                                                              1 × 1              MHP    FNAC (IC)-CEN                                                  S-100 + ve                                                                     1 year      no           no   cellular

  Vera- Sirera et al [@JR1041sr-49]             2017   26/F         Spain     \>10                       painless swelling                                                     3 × 2              LSP    FNAC (IC)- CEN                                                 S-100, CD-34, EMA, CD-117 & FVIII-RA + ve                                      14 months   no           no   ancient

  Gueiros et al [@JR1041sr-50]                  2017   26/M         Brazil    1/6 (5 days)               painless nodule                                                       2 × 2              RHP    Incision Bx-CEN                                                NI                                                                             30 months   no           no   cv

  Melo et al [@JR1041sr-51]                     2018   18/m         Brazil    36                         painless lesion                                                       3.5 × 3            RHP    Incision Bx-CEN                                                S-100 + ve                                                                     1 year      no           no   cv

  Khalele et al [@JR1041sr-52]                  2018   33/F         Egypt     28                         painless swelling, discomfort in mastication                          2 × 3              RHP    FNAC(IC)-CEN                                                   S-100 + ve; NF -ve                                                             NI          no           no   cv

  Murakami et al [@JR1041sr-53]                 2018   17/F         Japan     12                         swelling, pharyngeal pain and redness                                 2 × 1.9            MSP    WLE; buccinator myomucosal flap closure                        S-100 + ve                                                                     6 months    no           no   cv

  Present case                                  2016   16/F         India     2                          painless swelling                                                     2.5 × 2            LSP    CEN                                                            S-100 + ve & SOX-10 + ve                                                       1 year      no           no   cv
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations** : +ve, positive; Bx, biopsy; CEN, complete excision with narrow margin; cv, conventional variant; EHP, entire hard palate; EMA, epithelial membrane antigen; F/U, follow-up duration; F, female; FB, foreign body; FNAC, fine needle aspiration cytology; GFAP, glial fibrillary acidic protein; HP, hard palate; IC, inconclusive; ID, Incidentally detected; IHC, immunohistochemistry; LHP, left hard palate; LSP, left soft palate; M, male; MHP, midline hard palate; mo, month/months; MSP, midline soft palate; MT, malignant transformation; NF, neurofilament; NFLA, neurofibroma-like areas; NI, not informed; NSE, neuron specific enolase; plx, plexiform variant; RHP, right hard palate; RSP, right soft palate; SMA, smooth muscle actin; SOX-10, SRY-related HMG-box 10; SP, soft palate; -ve, negative; WLE, wide local excision; yr, year/years.

###### Updated clinical profile of reported cases of palatal schwannomas

  -----------------------------------------------------------------------------------------------------------------------------------------
  Clinical features of 46 patients with palatal schwannomas                                      
  ----------------------------------------------------------- ---------------------------------- ------------------------------------------
  Female                                                      29 (64%)                           45

  Mean age at time of initial evaluation, years old           30.04 (range: 3--84)               46

  Mean duration of lesion, months                             25.63 (range: 5 days-- 20 years)   38

  Cases reported from India                                   15 (32.6%)                         46

  Hard palate involvement                                     31 (67.4%)                         46

  Soft palate involvement                                     15 (32.6%)                         46

  Mean size of lesion, centimeters                            2.4 (range: 1--5)                  44

  Symptomatic cases                                           41 (89%)                           46

  Asymptomatic cases/ cases detected incidentally             5 (11%)                            46

  Symptoms at initial presentation                                                               

   Painless swelling/nodule                                   40 (87%)                           46

   Painful lesion/ pharynx pain                               2 (4.3%)                           46

   Dysphagia                                                  5 (10.9%)                          46

   Dysphonia                                                  3 (6.5%)                           46

   Dyspnea                                                    1 (2.2%)                           46

   Difficulty in mastication                                  4 (8.7%)                           46

   Bleeding from tumor                                        2 (4.3%)                           46

   Foreign body sensation                                     1 (2.2%)                           46

   Pharyngeal erythema                                        1 (2.2%)                           46

  Signs at initial presentation                                                                  

   Tenderness over lesion                                     2 (4.3%)                           46

   Soft on palpation                                          4 (8.7%)                           46

   Ulcerated overlying mucosa                                 8 (17.4%)                          46

  Histological variant                                                                           

   Conventional                                               40 (87%)                           46

   Plexiform                                                  3 (6.5%)                           46

   Ancient                                                    2 (4.3%)                           46

   Cellular                                                   1 (2.2%)                           46

  IHC positive staining                                                                          27 [b](#FN1041sr-4){ref-type="table-fn"}

   S-100                                                      27 (100%)                          

   Vimentin                                                   3 (11.1%)                          

   EMA                                                        2 (3.7%)                           

   SOX-10                                                     1 (3.7%)                           

   NSE                                                        1 (3.7%)                           

   GFAP                                                       1 (3.7%)                           

   CD-56 & CD-57                                              1 (3.7%)                           

   CD-34 & CD-117                                             1 (3.7%)                           

  Surgical treatment                                                                             46

   Enucleation/complete excision with\                        33 (71.7%)                         
   narrow margin/excision biopsy                                                                 

   Wide margin excision                                       11 (24%)                           

   Partial maxillectomy                                       1 (2.2%)                           

   En bloc resection                                          1 (2.2%)                           

  Prognosis                                                                                      46

   Recurrence                                                 1 (2.2%)                           

   Malignant transformation                                   0 (0%)                             
  -----------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: EMA, epithelial membrane antigen; GFAP, glial fibrillary acidic protein; SOX-10, SRY-related HMG-box 10.

Number (%) unless otherwise specified.

Number of cases in which some form of immunohistochemistry staining was performed.

Out of 46 compiled cases, 29 were female (64%), and 16 were male (in 1 case, no gender was reported). [@JR1041sr-45] The ages ranged from 3 to 84 years old, with an average of 30.04 years old. The mean duration of the lesion from 38 reported cases was of 25.63 months (range: 5days--20 years), while in the remaining 8 cases no information about the duration of the tumor could be retrieved (either the exact numerical duration was not stated, or the lesion was incidentally detected). [@JR1041sr-10] [@JR1041sr-17] [@JR1041sr-33] [@JR1041sr-38] [@JR1041sr-39] [@JR1041sr-44] [@JR1041sr-46] [@JR1041sr-47] Some articles reported the duration of onset in days, weeks or years. Therefore, the approximate lesional age was converted and charted into months. The incorporated cases were reported from 13 countries: India ( *n = * 15), USA ( *n = * 5), Brazil ( *n = * 5), Japan ( *n = * 4), Spain ( *n = * 3), Turkey ( *n = * 3), UK ( *n = * 2), Germany ( *n = * 2), Iran ( *n = * 2), Italy ( *n = * 2), Greece ( *n = * 1), Morocco ( *n = * 1), and Egypt ( *n = * 1) ( [Fig. 7](#FI1041sr-7){ref-type="fig"} ). The majority of the cases has been reported from India, indicating either a high prevalence or a greater awareness about the disease in that country.

![Worldwide distribution of reported cases of palatal schwannomas.](10-1055-s-0039-1692635-i1041sr-7){#FI1041sr-7}

The tumor involved the soft and the hard palate in 15 (32.6%) and in 31 (67.4%) subjects, respectively. Among the 15 soft palatal lesions, 8 involved the right side, 5 involved the left side, 1 was in the midline, and no specific site over the soft palate was mentioned in 1 case. [@JR1041sr-22] Out of 31 hard palatal lesions, 13 were confined to the right hard palate, 11 involved the left side, 5 were in the midline, 1 involved the entire hard palate, and no specific hard palatal location was reported in 1 case. [@JR1041sr-29]

Most of the articles mentioned the width and length of the lesion, but the depth dimension is rarely reported. The largest diameter/dimensions of the tumor ranged from 5 cm to 1 cm, with an average of 2.4 cm (no information about the dimension of the lesion was reported in 2 cases). [@JR1041sr-13] [@JR1041sr-17] When studying for an association between the duration of the lesion and lesion size, we found a weak positive correlation (r = 0.25). However, the correlation is statistically insignificant ( *p*  = 0.13) ( [Fig. 8](#FI1041sr-8){ref-type="fig"} ).

![Relationship between lesion size and duration of lesion.](10-1055-s-0039-1692635-i1041sr-8){#FI1041sr-8}

Symptoms were commented in 41 cases (89%). The remaining 5 cases were incidentally detected or asymptomatic. Painless swelling/nodule was the most common symptom, present in 40 cases (87%). One case reported delayed pain over the tumor [@JR1041sr-37] while in another patient, pharyngeal pain was present. [@JR1041sr-53] Other symptoms were reported in the following frequency: dysphagia ( *n * = 5) [@JR1041sr-14] [@JR1041sr-23] [@OR1041sr-25] [@JR1041sr-31] [@JR1041sr-41] dysphonia/garbled speech ( *n*  = 3) [@JR1041sr-14] [@OR1041sr-25] [@JR1041sr-35] , dyspnea ( *n * = 1) [@JR1041sr-35] , difficult mastication (n = 4) [@JR1041sr-13] [@JR1041sr-23] [@JR1041sr-27] [@JR1041sr-52] , occasional bleeding (n = 2) [@JR1041sr-18] [@OR1041sr-25] , foreign body sensation ( *n = * 1) [@JR1041sr-14] , difficulty in oral hygiene ( *n = * 1) [@JR1041sr-35] and pharyngeal redness ( *n * = 1) [@JR1041sr-53] .

Clinically, most of the lesions were reported as nontender and/or firm/hard. Tenderness was elicited only twice [@JR1041sr-21] [@JR1041sr-37] , while soft swelling on palpation was reported in four cases [@JR1041sr-18] [@JR1041sr-38] [@JR1041sr-43] [@JR1041sr-44] . Jones et al reported a cystic component in the lesion. [@JR1041sr-11] Most of the lesions had a healthy overlying mucosa without any obvious ulceration. Ulceration of the overlying mucosa was noted in seven other cases apart from present case. [@JR1041sr-13] [@JR1041sr-23] [@JR1041sr-30] [@JR1041sr-31] [@JR1041sr-34] [@JR1041sr-37] [@JR1041sr-44] The low frequency of ulceration reflects a good encapsulation of this tumor.

Of the histological variant, the conventional subtype dominated and was reported in 40 cases (87%). It was followed by plexiform-3, [@JR1041sr-13] [@JR1041sr-24] [@JR1041sr-29] ancient-2, [@JR1041sr-32] [@JR1041sr-49] and cellular variant- 1. [@JR1041sr-48] Almost all of the cases with conventional phenotype exhibited Verocay bodies and a predominance of Antoni A areas over Antoni B areas. The additional presence of acute and chronic inflammatory infiltrate, [@JR1041sr-23] areas of hyalinization, and thin blood vessels with/without thrombus/fibrin, [@JR1041sr-11] [@JR1041sr-28] [@JR1041sr-30] [@JR1041sr-31] [@JR1041sr-46] and areas containing epithelioid cells have also been reported from cases with conventional phenotypes. [@JR1041sr-46] In one report, a note was made about the predominance of neurofibroma-like areas. [@JR1041sr-21]

Various IHC staining were performed in 27 patients. S-100 staining was employed in all of the 27 amenable cases, and showed strong immunoreactivity in all of the employed cases. Other authors revealed varying degrees of positive immunoreactivity with different stains: vimentin, [@JR1041sr-15] [@JR1041sr-19] [@JR1041sr-42] epithelial membrane antigen (EMA), [@JR1041sr-24] [@JR1041sr-49] SOX-10 (present case), neuron specific enolase (NSE), [@JR1041sr-15] glial fibrillary acidic protein (GFAP), [@JR1041sr-24] CD-56 and CD-57, [@JR1041sr-24] and CD-34 and CD-117. [@JR1041sr-49] Immunonegative results were noted with the following stains: actin, [@JR1041sr-21] neurofilament protein (NFP), [@JR1041sr-24] [@JR1041sr-52] smooth muscle antigen, [@JR1041sr-37] cytokeratin, [@JR1041sr-46] AE1/AE3, [@JR1041sr-24] and Calponin. [@JR1041sr-24]

Various imaging modalities capable of revealing abnormal palatal morphologies were performed on 36 patients, including simple X-ray scan in 1, panoramic radiography (orthopantomogram \[OPG\]) in 6, maxillary occlusal radiography in 7, CT scan (with or without contrast) in 20, magnetic resonance imaging (MRI) in 7, and positron emission tomography (PET) scan in 1 patient. The principal CT scan finding was an isodense-hypodense soft tissue lesion without any bony erosion/resorption. Partial/complete bony erosion was noted in 6 instances. [@JR1041sr-15] [@JR1041sr-16] [@JR1041sr-33] [@JR1041sr-37] [@JR1041sr-38] [@JR1041sr-51] The lesion was seen eroding into the right maxillary sinus through the floor of the sinus in one case; [@JR1041sr-15] while in another patient, the mass was seen invading the nasal cavity through the palatal bone. [@JR1041sr-38] Orthopantomogramand maxillary occlusal radiography showed mostly a radiolucent lesion, without any bony alteration or periapical changes. In MRI exams, the mass appeared hypo-to-isointense on T1-weighted images and hyperintense on T2-weighted images, in almost all of the cases. Small foci of central calcification were evident on MRI in one occasion. [@JR1041sr-40]

With the exception of two cases, all of the lesions were treated with simple surgical removal, either with enucleation, with wide local excision with a good margin, or with a complete resection without incorporating a wide margin. The remaining two cases were treated by partial maxillectomy, [@JR1041sr-38] and by en bloc resection. [@JR1041sr-12] The defect was either closed primarily or was allowed to heal by secondary intention. Otherwise, large defects were closed with some form of prosthesis, splints, grafts or flaps. Reconstruction using buccinator myomucosal pedicle flap, [@JR1041sr-30] [@JR1041sr-53] split-thickness skin graft, [@JR1041sr-38] palatal splint, [@OR1041sr-25] and collagen sheet have been reported by various authors. [@JR1041sr-15] [@JR1041sr-17]

Preoperative fine-needle aspiration cytology (FNAC) was performed in 10 cases, while incisional biopsy was performed in 13 cases. Fine-needle aspiration cytology was inconclusive in almost all of the cases.

Postoperative follow-up was performed in 29 cases, and the follow-up duration ranged from 11 days to a decade. Recurrence was noted only once, [@JR1041sr-13] while none of the included cases reported malignant transformation.

Discussion
==========

Schwannoma is synonymous with neurinoma, neurilemmoma, and perineural fibroblastoma. [@JR1041sr-22] It arises from cranial, peripheral, or autonomic nerves that contain Schwann cells. It never arises from cranial nerves I and II, since they lack Schwann cells. [@JR1041sr-16] Sensory nerve is more common, with rare involvement of motor nerve. [@JR1041sr-54]

About 25 to 45% of all schwannomas are found in the head and neck region, and only between 1 to 12% of them have an intraoral origin. [@JR1041sr-7] [@JR1041sr-8] [@JR1041sr-9] However, the palatal location is rare. In a review of 52 cases of schwannomas of the head and neck region, only 1 case of schwannoma over the hard palate was reported. [@JR1041sr-55] A review of the literature on oral, as well as on head and neck schwannomas, showed varying results about the gender predilection of the tumor. Williams et al showed a male predominance of the tumor; for Lucas et al, there was a greater predilection for females, [@JR1041sr-56] [@BR1041sr-57] while other authors reported no gender predilection. [@JR1041sr-58] [@BR1041sr-59] Although reported in all age groups, schwannomas are more common in the 2 ^nd^ and 3 ^rd^ decades of life. [@JR1041sr-21]

Intraoral and palatal schwannomas are mostly solitary lesions. [@JR1041sr-34] Multiple nerve schwannomas require evaluation for Von-Reklinghausen disease, while bilateral vestibular schwannomas raise suspicion for neurofibromatosis-II. [@JR1041sr-30] The majority of palatal schwannomas have been reported on the lateral aspect of the palate.

Based on its location, schwannomas have been classified either as central (bone) or peripheral (soft tissue) type. The tumor may arise centrally in the bone, may arise within the nutrient canal, or a soft tissue tumor may secondarily erode into the bony tissue. [@JR1041sr-60] There are two clinical forms of oral schwannomas: the encapsulated form, surrounded by dense fibrous connective tissue, and the pediculate/nonencapsulated form, in which the tumor is located just below the mucous membrane. [@JR1041sr-61]

Although the etiology of schwannomas is unknown, trauma is considered to be an unclear etiological cause. [@JR1041sr-2] There are various theories about its onset: 1) ectodermal tumor derived from Schwann cells; and 2) mesodermal tumor arising from the perineurium. [@JR1041sr-38]

Most of the cases are asymptomatic, while most of the lesions are slow-growing. A sudden increase in size may be due to internal hemorrhage. [@JR1041sr-16] The clinical presentation depends upon the site of the tumor, the size of the tumor, and upon the anatomy of the affected nerve. [@JR1041sr-32]

There are four major histological types of schwannoma: conventional, plexiform, cellular, and ancient variant. According to Erlandson, schwannomas are classified into seven subtypes: conventional, cellular, plexiform, cranial nerve, melanotic, ancient, and granular cell schwannomas. [@JR1041sr-62] However, they have mainly two distinct histological patterns: Antoni types A and B. Antoni patterns were first described by Prof. Nils Ragnar Eugene Antoni. Antoni A areas consist of a hypercellular proliferation of fusiform cells, often arranged in a palisading pattern around a central acellular eosinophilic area known as Verocay bodies, while Antoni B areas are hypocellular and less organized.

The conventional variant consists mostly of Antoni A areas and Verocay bodies, with the occasional presence of Antoni B areas. The additional presence of acute/chronic inflammatory infiltrate, areas of hyalinization, and thin vessels containing thrombin are noted in the conventional variant. [@JR1041sr-22] The cellular variant is characterized by a marked increase in cellularity, with a compact arrangement of spindle cells in fascicles, variable nuclear hyperchromasia and pleomorphism, lack of Verocay bodies, and a predominance of Antoni A areas. [@JR1041sr-48] [@JR1041sr-64] The cellular variant, due to the increased mitotic activity and to the high potential for body destruction, is often confused with sarcoma. [@JR1041sr-65]

The ancient variant is characterized by degenerative changes, such as calcification, mild pleomorphism and bizarre nuclei, microcyst formation, dilated vessels, and hemorrhagic phenomena. Some authors believe that the absence of symptoms and the long history of the lesion are the probable cause of transformation into an ancient variant. [@JR1041sr-32] The plexiform type consists of both Antoni A and B regions with prominent Verocay bodies, like the conventional variant; however, the Schwann cells show a nodular arrangement with capsular delineation. [@JR1041sr-24]

Immunohistochemistry is important to distinguish schwannoma from other close differentials, and can aid in its diagnosis; however, it is not mandatory to confirm the diagnosis. S-100 is undoubtedly the first immunostaining that comes into mind when dealing with suspected peripheral nerve tumors. Both schwannomas and neurofibromas show moderate to strong reactivity to S-100. However, S-100 has low specificity for diagnosing peripheral nerve cell tumors. One study has found Sox-10 to be more sensitive and specific than S-100 for peripheral nerve tumors. [@JR1041sr-66] Diffuse staining with CD-34 is seen in neurofibromas, while schwannomas only occasionally show some focal staining in noncellular (Antoni-B) areas. Calretinin staining is found to be highly specific for schwannoma and useful in differentiating it from neurofibroma. [@JR1041sr-67] [@JR1041sr-68] Intensive staining with CD-57 is noted in traumatic neuromas. [@JR1041sr-69] Schwannomas also stain positive with Leu-7antigen, GFAP, and vimentin. [@JR1041sr-18] The presence of axons in palisaded encapsulated neuroma (PEN) and, therefore, positive staining with NFP, distinguishes it from schwannomas. [@JR1041sr-70] Staining with AE1/AE3 and with calponin can help rule out salivary gland tumors. [@JR1041sr-24]

The major differentials are benign salivary gland tumors, benign peripheral nerve tumors (neurofibroma, traumatic neuroma, and PEN), other benign mesenchymal tumors (lipoma and hemangiomas), and odontogenic tumors. Salivary gland tumors are the most common differential in our review, and were considered in 25 cases (54.3%).

Imaging modalities such as CT and MRI are useful during the initial workup to know the extent of the tumor, to delineate any bony erosion, to identify the nerve of origin, and to narrow the differentials. [@JR1041sr-14] [@JR1041sr-16] [@JR1041sr-19] [@JR1041sr-21] Yamazaki et al reported a case of a rapid growing lesion which was found in MRI to be originating from the mental nerve; therefore, the imaging exam assisted in the preoperative diagnosis of a peripheral nerve tumor that was otherwise considered a malignant lesion. [@JR1041sr-71] Schwannomas mostly appear iso- to hypointense on T1-weighted MRI images and hyperintense on T2-weighed MRI images. Computed tomography scans generally show a well-circumscribed, soft tissue lesion without any bony erosion. However, schwannomas can occasionally cause pressure erosion of the bone. [@JR1041sr-42] [@JR1041sr-72] The proportion of Antoni-A and B areas has been reported to have a significant influence on the imaging findings. Gomez-Brouchet et al reported that vestibular schwannomas with a homogeneous appearance on MRI were predominantly made of Antoni-A tissues, while those with heterogeneous/cystic features were predominantly composed of Antoni-B/mixed tissues. [@JR1041sr-73]

The therapy of choice consists of complete surgical removal. Schwannomas do not recur if they are completely removed. Only one case of benign palatal schwannoma has been found to recur after excision. [@JR1041sr-13] Malignant transformation of head and neck schwannomas are exceedingly unusual, although it has been reported. [@JR1041sr-74] [@JR1041sr-75]

Final Comments
==============

There is barely any paper in the literature focusing extensively on palatal schwannomas, and tackling this benign tumor as an individual entity. Despite divergent inferences from different articles, the following conclusions can be drawn:

-   Predominance in females, and involvement of the hard palate is twice the involvement of the soft palate.

-   Although reported in all age groups, schwannomas commonly present during the 2 ^nd^ or 3 ^rd^ decades of life.

-   Slow-growing tumor with a mean lesion duration of 25.63 months.

-   Mostly present on the lateral aspect of the palate, with occasional reports of midpalatal or panpalatal lesions.

-   Almost always a solitary tumor, presenting as a painless, nontender, and firm swelling.

-   The conventional variant is the most common histological phenotype.

-   Imaging can add to suspicion and can delineate a differential diagnosis, but the diagnosis is confirmed by pathological examination.

-   Benign tumor of the salivary gland is the most common clinical differential.

-   Fine-needle aspiration cytology is mostly inconclusive. Immunohistochemistry can assist in confirming a diagnosis, but is more helpful to rule out close differentials.

-   Complete surgical removal is the treatment of choice.

-   Recurrence and malignant transformation are extremely rare.
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